corporate briefing session the searle company
TRANSCRIPT
The Searle CompanyT O L E A D I N I M P R O V I N G T H E Q U A L I T Y O F H U M A N L I F E
CORPORATE BRIEFING SESSION
2
Brief history of IBLPA R T N E R S H I P, I N T E G R I T Y, PA S S I O N & E X C E L L E N C E
• The Group began its operations several generations ago with the inception of a distribution house. In 1887 it became distributors for W.D. & H.O. Wills cigarettes for all the pre-partition Indian sub-continent including Burma and Ceylon. As the business progressed over the next few decades, the Group established offices in several major cities, including Karachi and Lahore
• In 1993 IBL, bought the local operations of G.D. Searle, an American pharmaceutical manufacturer and successfully manages that operations to date.
• Other new companies were established to manage IBL’s businesses according to product lines and industries in a better and more organized way, and thus, IBL became the IBL Group.
3
O U R FA M I LY A N D T H E I R A F F I L I AT E S
IBL Business Operations
IBL
Brief history of SearlePA R T N E R S H I P, I N T E G R I T Y, PA S S I O N & E X C E L L E N C E
• Originally founded in US in 1888 by Gideon D. Searle.
• Incorporated in Pakistan as a Private Limited Company in 1965 as a subsidiary of G.D. Searle & Co., USA.
4
Our FootprintT O U C H I N G L I F E O F M I L L I O N S B Y B R I N G I N G E X C E L L E N C E I N C O M M E R C I A L O P E R AT I O N S
A Passionate Team of
Medical Sales Professionals Serving the Nation
1,900
4 Brands
Billion Rupee Club
No.
1i. Cardiovascular ii. Pain Management iii. Gynae and Obsiv. Cough Suppressant
Largest Pharmaceutical Company
2ND
In terms of Product Consumptions(Unit)
1BillionPlus
500MnPlus
7 Brands
500 Million Plus Club
18%
Growing with Double Digit on 13 yr horizon
CAGR 13 YR
>650,000Everyday
Prescriptions are prescribed by Doctors
No.
2i. Pulmonology ii. Neurology and Pediatrics
No.
3i. Anti-Infectives
Our PromiseC O M M I T M E N T T O E X C E L L E N C E
6
01
02
03
04
Searle was ranked as the most outstanding company in Pakistan as per Asiamoney’s Outstanding Companies Poll, 2018.
Searle since 2018, has been a part of Forbes Asia’s Best Under A Billion rankings for four consecutive years.
Searle was included in Financial Times Stock Exchange Index, a London based index, for international investors to track their funds in 2017.
As per MSCI, Searle was top ranked listed entity of Pakistan with the highest performance growth of 52% in share prices.
Our Product PortfolioM A R K E T I N G A U T H O R I Z AT I O N
15Biotech
Registration
288Global
Registration
25Enlistments
6Drug
Manufacturing License
470Local
Registration
18Medical Device
Registration
Our BrandsL E A D I N G B R A N D S I N T H E I R T H E R A P E U T I C A R E A
8
• HydryllinCough
• NuberolMuscle
Relaxant
• PeditralORS
• Extor, Spiromide, Byscard
Cardiovascular
• Tramal, RotecAnalgesic
• Gravinate, Lomotil, Selanz
Gastrointestinal
• Venofer, FerinjectIron Plain
• Tainem, InvanzAntibiotics
• DecaderonCorticosteroid
• SustecNitrites & Nitrates
• SinemetAnti Parkinson
Our PartnersT R U S T O F O U R A F F I L I AT O R S
9
Existing Market - 15
Future Market - 7
Our PresenceO U R B O N D W I T H T H E G L O B A L V I L L A G E
Afghanistan
Sri Lanka
Myanmar
Laos
Vietnam
Cambodia
Senegal
Ivory Coast
Ghana
Nigeria
Cameroon
Sudan
Ethiopia
Yemen
Tanzania
Kenya
Uganda
Mauritius
Maldives
PhilippinesRwanda
Oman
Guatemala
Our FacilitiesS TAT E - O F - T H E - A R T FA C I L I T I E S
• Karachi Plant 1 (GD Searle)
• Karachi Plant 2 (MSD)
• Lahore Plant 1; Lahore Plant 2
Searle Company Limited
• Nextar Plant Port QasimSearle Biosciences
• Lahore IV FacilitySearle Laboratories
• Consumer FacilitySearle Consumer
6 Manufacturing Facilities
Producing
>250MillionUnits Annually
CERTIFICATIONS
Our R&D CENTER
TSCL has established a state-of-
the-art Research & Development
Centre at ICCBS Technology Park
with first of its kind technology
incubator in Pakistan.
I N T E R N AT I O N A L C E N T E R F O R C H E M I C A L A N D B I O L O G I C A L S C I E N C E S ( I C C B S ) , U N I V E R S I T Y O F K A R A C H I
340,499,281
208,042,622
192,321,726
160,995,167
126,603,463
125,350,831
123,038,392
91,256,969
85,934,218
84,158,023
GSK
Searle
Abbot
Sami
MartinDow
GSK Con
Getz
Atco
Barret
Bosch
Growth %
-4.23%
17.95%
0.53%
7.60%
7.25%
8.05%
2.88%
3.51%
-0.46%
-1.48%
11.52%
7.04%
6.51%
5.45%
4.28%
4.24%
4.16%
3.09%
2.91%
2.85%
Industry RankingsSEARLE IS RANKED NUMBER 2ND IN TERMS OF VOLUME AND RANKEND 4TH IN TERMS OF VALUE
2020 – VOLUME IMS MAT SEPTEMBER
33,435,849,263
30,474,276,785
29,749,584,139
28,084,578,651
26,775,274,409
21,009,215,334
16,016,737,326
15,197,233,436
14,007,419,618
13,572,637,277
GSK
Getz
Abbott
Searle
Sami
Martin Dow
GSK Con
High-Q
Hilton
Bosch
Growth %
7.20%
12.05%
13.48%
17.31%
16.63%
16.95%
26.66%
3.95%
3.05%
9.69%
2020 – VALUE IMS MAT SEPTEMBER
6.88%
6.28%
6.13%
5.79%
5.52%
4.33%
3.30%
3.13%
2.89%
2.80%
Market Share Market Share
10.31% 0.94%
Our VolumeSEARLE JUMPED FROM BEING AT NUMBER 8TH IN 2008 TO NUMBER 2ND IN 2020 IN THE IMS RANKING WITH REFERENCE TO REVENUE IN TERMS OF UNITS SOLD
208,042
198,157
176,602
161,338
115,000
107,000
100,000
84,000
76,000
72,000
80,000
71,000
56,000
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Rank
3rd
2nd
4th4th
5th
6th
6th
6th
7th
7th
8th
Searle has a large and sustainable customer base because of more focus on the treatment of chronic diseases.
3rd
3rd
2nd
Val
ue
in T
ho
usa
nd
s
28,084
26,776
22,843
17,163
12,811
11,790
9,809
8,078
6,849
5,696
5,000
4,300
3,300
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Rank
6th
5th
6th
7th
8th
8th
8th
8th
9th
11th
Our PositionSEARLE JUMPED FROM BEING AT NUMBER 11TH IN 2008 TO NUMBER 4TH IN 2020 IN THE IMS RANKING WITH REFERENCE TO REVENUE IN TERMS OF VALUE
5th
4th
4th
Val
ue
in M
illio
ns
Our RevenueT H E R E V E N U E I N S E A R L E I N C R E A S E D R A P I D LY D U R I N G T H E L A S T 2 0 Y E A R S
2000 20202008
Management change
The revenue of the company grown from 2.7 billion in 2008 to 20.4 billion in 2020, representing an average growth rate of 18.31% per annum
The revenue in 2000 was 1.3 billion and were 2.0 billion till 2008 representing an average growth of only 9.2%
1.3 billion2.7 billion
20.4billion
Our ProfitsT H E P R O F I T W H I C H S E A R L E U S E D T O M A K E I N 2 0 0 7 N O W R E P R E S E N T S O N LY N I N E D AY S O F P R O F I T
2000 2020
35.17
million
2.54
billion
The profits increased sharply during the last 13years from just 64 million in 2007 to 2.54 billion in the year 2020, representing an average growth rate of 32.84%.
The reduction in net profits from 2018 is mainly due to increase in PKR-USD exchange rate (121/$-168/$) and increase in finance cost due to a sharp rise in inter-bank borrowing rates.
2007
63.54
million
Profits were unstable during 2000 to 2007 representing a much lower average growth rate of 10%.
Our Strategy
18
N E W V S . E X I S T I N G P R O D U C T P E R C E N TA G E
47% 46% 46% 43%
41% 40%
53% 54% 54%57%
59% 60%
2015 2016 2017 2018 2019 2020
54%46%
Old New
44%56%
39%61%
New products within top 10
Rapid increase in share of top
10 products:
- 2013 - 46%
- 2015 - 56%
- 2017 - 61%
Financial Information
Standalone Financials
2020 2019 2018
Revenue 16,567,219 14,537,198 12,675,110
PFO % 23.82% 22.41% 27.13%
PAT % 14.82% 18.17% 24.06%
EPS 11.56 12.44 14.35
Cash Dividend 25.00% 25.00% 50.00%
Bonus Dividend 0.00% 0.00% 15.00%
Consolidated Financials
2020 2019 2018
Revenue 20,474,842 18,062,107 16,148,468
PFO % 21.22% 18.11% 21.50%
PAT % 12.44% 12.54% 16.82%
EPS 11.77 10.55 12.65
Our FutureB L A Z I N G T O WA R D S A R A D I A N T F U T U R E
20
Will be the number 1 pharmaceutical company in Pakistan
Will have global presence in more than 50 countries
Will have the largest field force of highly trained medical representatives
Will have FDA approved manufacturing facilities
01
02
03
04
Corporate Social ResponsibilityR E S E A R C H I N T H E S E R V I C E O F M A N K I N D
• Searle is committed towards saving environment and creating a sustainable clean future. Searle plans to plant 300 thousands trees in various parks around the city of Karachi.
• Searle won the National Forum for Environment and Health CSR Awards in 2016, for those who have contributed to the society and science.
• Searle awarded a substantial grant to ICCBS for strengthening of genomic research.
• Renovated AKAR Hospital located in Karachi, as total non-profit organization working entirely on donations from the company, and restocked medicines for the hospital pharmacy.
21
Our Commitment to Society
22
R E S E A R C H I N T H E S E R V I C E O F M A N K I N D